Trial Profile
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Fisogatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man
- Sponsors Blueprint Medicines
- 10 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Aug 2022 Planned End Date changed from 1 Mar 2022 to 31 Dec 2022.
- 10 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.